TDM for Optimized Outcome in Patients With mRCC.
Launched by NIELS FRISTRUP · Dec 2, 2020
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "TDM for Optimized Outcome in Patients With mRCC," is focused on understanding how monitoring the levels of cancer treatment drugs in the blood can help improve outcomes for patients with metastatic renal cell carcinoma (mRCC), a type of advanced kidney cancer. The study will also look at how certain genetic factors and the presence of antibodies might affect how well patients respond to immunotherapy, a treatment that helps the body’s immune system fight cancer.
To participate in this trial, patients must be living in Denmark and have been diagnosed with metastatic renal cell carcinoma that is being treated medically. All adult patients are welcome, but they need to provide written consent to join. Those who take part will have their blood levels of treatment drugs monitored and may undergo additional tests related to their genetic makeup. This information could help doctors tailor treatments better and manage side effects more effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients in Denmark with medically treated metastatic renal cell carcinoma.
- Exclusion Criteria:
- • No written informed consent.
About Niels Fristrup
Niels Fristrup is a distinguished clinical trial sponsor dedicated to advancing medical research and enhancing patient outcomes through innovative studies. With a strong emphasis on ethical practices and regulatory compliance, the organization collaborates with leading healthcare professionals and institutions to design and implement rigorous clinical trials across various therapeutic areas. Niels Fristrup is committed to fostering scientific integrity and transparency, ensuring that all trials are conducted with the highest standards of quality and safety. Their mission is to contribute to the development of effective therapies that address unmet medical needs and improve the lives of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Herlev, , Denmark
Herlev, , Denmark
århus C, Danmark, Denmark
Odense, , Denmark
Aarhus, Danmark, Denmark
Patients applied
Trial Officials
Niels Fristrup, MD, PhD
Principal Investigator
University of Aarhus
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials